Supported by the Health Industry Research Program of Gansu Province,No.GSWSKY2021-043;the Youth Science and Technology Foundation of Gansu Province,No.22JR11RA002;the Natural Science Foundation of Gansu Province,No.22JR5RA008.
BACKGROUND The treatment of gastric cancer remains highly challenging,particularly in cases of unresectable locally advanced or metastatic disease.Although chemotherapy and immunotherapy have shown some efficacy in su...
Supported by The Health Commission of Zhejiang Provence,China,No.WKJ-ZJ-2136.
BACKGROUND Palliative care for unresectable pancreatic cancer(PC)focuses mainly on the symptoms of the disease,including abdominal pain,obstructive jaundice,and malnutrition.Biliary stent placement using endoscopic re...
Supported by the Guangzhou Science and Technology Plan Project,No.2023A04J0419;National Natural Science Foundation Cultivation Project at the Third Affiliated Hospital of Sun Yat-sen University,No.2022GZRPYQN04.
BACKGROUND Intrahepatic cholangiocarcinoma(iCCA)is the second most common liver malignancy with poor prognosis and limited treatment options.AIM To identify the most effective drug for transarterial chemoembolization(...
Hepatocellular carcinoma(HCC)is one of the leading causes of cancer-related mortality worldwide.A substantial proportion of patients are diagnosed with advanced or intermediate-advanced stage disease at presentation a...
BACKGROUND The combination of anti-epidermal growth factor receptor(EGFR)therapy and chemotherapy is currently a preferred first-line treatment for patients with unre-sectable,RAS and BRAF wild-type,left-sided metasta...
In the recent issue of the World Journal of Gastroenterology,Han et al compared the efficacy of and adverse reactions to bevacizumab versus lenvatinib as molecularly targeted agents in combination with interventional ...
supported by Jiangsu Hengrui Pharmaceuticals and the following grants:the National Natural Science Foundation of China(NSFC:82321003,82173128,82073377,81930065);the Natural Science Foundation of Guangdong(2021A1515012439);Guangdong Basic and Applied Basic Research Foundation(2024B1515020120);the CAMS Innovation Fund for Medical Sciences(CIFMS:2019-I2M-5-036);Additional funding was provided by the Cancer Innovative Research Program of Sun Yat-sen University Cancer Center(CIRP-SYSUCC-0004).
This phase 2/3 trial (NCT04856787) assessed the efficacy and safety of SHR-1701, a bifunctional protein targeting PD-L1 and TGF-β,in combination with BP102 (a bevacizumab biosimilar) and XELOX (capecitabine plus oxal...
supported by the National Natural Science Foundation of China(82273126 and 82273407);the Collaborative Innovation Cluster Project of the Shanghai Municipal Health Commission(grant number,2020CXJQ03);the Innovative research teams of high-level local universities in Shanghai.The authors thank all patients,their families,investigators,and research staffs for participating in this trial.
This multicohort phase II trial(ALTER-G-001;NCT05262335)aimed to assess the efficacy offirst-line anlotinib plus chemotherapy for gastrointestinal(GI)cancer patients with unresectable liver metastases.Eligible patient...
supported by Beijing Science and Technology Innovation Medical Development Foundation(grant no.KC2021-JX-0186-106).
Previous studies showed encouraging efficacy of alternating FOLFOX/FOLFIRI for metastatic colorectal cancer(mCRC).This phase 2 trial(NCT04324476)aimed to evaluate efficacy and safety of alternating modified CAPOX(cape...
Supported by Scientific Research project of Hunan Provincial Health Commission,No.B202303077689;Hunan Natural Science Foundation Project,No.2023JJ40397.
BACKGROUND Transhepatic arterial chemoembolization(TACE),as a local treatment,has been widely used in the treatment of unresectable liver cancer.The introduction of drug carrier microspheres has brought new hope for t...